% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Taieb:303095,
      author       = {J. Taieb and D. P. Modest$^*$ and M. Fakih and F.
                      Ciardiello and E. Van Cutsem and E. Elez and C. Gravalos and
                      A. C. Bragagnoli and V. Barboux and L. Roby and N. Amellal
                      and G. W. Prager},
      title        = {{I}mpact of trifluridine/tipiracil plus bevacizumab on
                      tumor shrinkage and depth of response in refractory
                      metastatic colorectal cancer: analysis of the {SUNLIGHT}
                      trial.},
      journal      = {European journal of cancer},
      volume       = {227},
      issn         = {0959-8049},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01520},
      pages        = {115644},
      year         = {2025},
      abstract     = {This post hoc analysis of the SUNLIGHT trial sought to
                      assess the response to treatment with trifluridine/tipiracil
                      (FTD/TPI) + bevacizumab and FTD/TPI in patients with
                      refractory metastatic colorectal cancer using tumor
                      shrinkage (TS), early TS (ETS), duration of TS (DTS) and
                      depth of response (DpR) as response-related parameters.TS
                      was defined as any decrease from baseline of the sum of the
                      longest diameter of target lesions. TS at first assessment
                      was specified as ETS. DpR was defined as the maximum
                      percentage change from baseline of the sum of the longest
                      diameters of target lesions. DTS was defined as the time
                      from first TS to first increase in tumor size, progressive
                      disease, or death.In the FTD/TPI + bevacizumab group, 48
                      $\%$ had TS and 39 $\%$ had ETS. In the FTD/TPI group, 21
                      $\%$ had TS and 17 $\%$ had ETS. In patients achieving ETS,
                      median DTS was prolonged with FTD/TPI + bevacizumab compared
                      to FTD/TPI (3.8 versus 2.1 months; HR: 0.34 [95 $\%$ CI:
                      0.22, 0.53]; P < 0.0001). Magnitude of DpR was greater with
                      FTD/TPI + bevacizumab than with FTD/TPI.The survival benefit
                      of treatment with FTD/TPI + bevacizumab versus FTD/TPI is
                      likely associated with the improvement of ETS and DpR.},
      keywords     = {Bevacizumab (Other) / Colorectal cancer (Other) / Depth of
                      response (Other) / Response parameters (Other) /
                      Trifluridine/tipiracil (Other)},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40694985},
      doi          = {10.1016/j.ejca.2025.115644},
      url          = {https://inrepo02.dkfz.de/record/303095},
}